Pacira BioSciences, Inc. (PCRX)

NMS – Real vaqt narxi. Valyuta: USD

22.84

+0.10 (0.44%)

Yopilishda: May 12, 2026, 4:00 PM EDT

23.00

+0.16 (0.70%)

Bozor oldidan: May 13, 2026, 9:02 AM EDT

12.05.2026

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter to stockholders in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.

08.05.2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on May 4, 2026 to ten new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

05.05.2026

Pacira BioSciences Mails Letter to Stockholders

Details Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board's Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has mailed a letter to stockholders in connection with the Company's 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.

01.05.2026

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce the completion of its acquisition from an arm's length vendor (the “Vendor”) of the prescription files, patient records and related operational data (collectively, the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp's existing PharmaChoice-bannered pharmacies in Western Canada (the “Acquisition”). The purchase price for the Acquisition was $300,000, subject to customary adjustments, and was satisfied with cash on hand. No finder's fees were payable in connection with the Acquisition.

01.05.2026

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.

01.05.2026

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

30.04.2026

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce that it has entered into definitive share purchase agreements, each dated April 28, 2026 (collectively, the “Agreements”) to acquire from two arm's length vendor groups (collectively, the “Vendors”) a 100 percent interest in eight PharmaChoice Canada bannered pharmacies located in Eastern Canada (the “Acquisitions”), representing a meaningful expansion of the Corporations geographical footprint and operating scale.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

08.05.2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05.05.2026

Pacira BioSciences Mails Letter to Stockholders

01.05.2026

Pacira BioSciences, Inc. (PCRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

Videolar

No Data

Press-relizlar

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

Videolar

No Data

Press-relizlar

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Search stocks

Pacira BioSciences, Inc. (PCRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

Videolar

No Data

Press-relizlar

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

Videolar

No Data

Press-relizlar

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Mails Letter to Stockholders

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada